NCT06100874 - A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 20, 2023

Primary Completion Date

November 30, 2026

Study Completion Date

November 30, 2027

Conditions

Her 2 Positive Breast CancerBreast Cancer FemaleBreast Cancer Metastatic

Interventions

DRUG

Sacituzumab Govitecan

Trop-2-directed antibody-drug conjugate, 180 mg single-dose glass vial, via intravenous infusion per protocol.

DRUG

Trastuzumab

Humanized IgG1 kappa monoclonal antibody, 150mg single-dose vial, via intravenous infusion per protocol.

DRUG

Trastuzumab and Hyaluronidase-oysk

Recombinant monoclonal antibody, 6 mL vial, via subcutaneous injection per protocol.

Trial Locations (4)

RECRUITING

Miami Cancer Institute at Baptist Health, Miami

RECRUITING

SCRI Oncology Partners, Nashville

RECRUITING

Dana Farber Cancer Institite, Boston

RECRUITING

DFCI @ South Shore Hospital, South Weymouth